GlaxoSmithKline is set to launch its COPD ... had been able to engage with payers much earlier than on previous Ellipta products, which he believes has set it up for a strong launch.

GSK’s new asthma drug Relvar Ellipta has shown itself to be superior to existing treatments in a major real world trial, the Salford Lung Study (SLS). Developed with US respiratory specialist ...

GSK) chronic obstructive pulmonary disease (COPD) treatments, Trelegy Ellipta and Breo Ellipta. Under the Inflation Reduction Act, CMS is negotiating prices for select Medicare Part D drugs.

GSK plc. GSK will report first ... In the first quarter, higher sales of newer products like Arexvy, Cabenuva, Juluca, Dovato, Trelegy Ellipta and Shingrix are likely to have offset the decline ...

It has been about a month since the last earnings report for GSK (GSK). Shares have added about 8% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to ...

The Institute for Clinical and Economic Review (ICER) has published a special report on chronic obstructive pulmonary disease (COPD) therapies as part of the Centers for Medicare & Medicaid Services ...